Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Head and Neck Cancer

  Free Subscription


Articles published in J Nucl Med

Retrieve available abstracts of 62 articles:
HTML format



Single Articles


    February 2021
  1. BODET-MILIN C, Faivre-Chauvet A, Carlier T, Ansquer C, et al
    Anti-CEA pretargeted Immuno-PET shows higher sensitivity than DOPA-PET/CT to detect relapsing metastatic medullary thyroid carcinoma: Post- hoc analysis of the iPET-MTC study.
    J Nucl Med. 2021 Feb 5. pii: jnumed.120.252791. doi: 10.2967/jnumed.120.252791.
    PubMed     Abstract available


    October 2020
  2. NISHIO N, van den Berg NS, Martin BA, van Keulen S, et al
    Photoacoustic Molecular Imaging for the Identification of Lymph Node Metastasis in Head and Neck Cancer using an anti-EGFR Antibody-Dye Conjugate.
    J Nucl Med. 2020 Oct 2. pii: jnumed.120.245241. doi: 10.2967/jnumed.120.245241.
    PubMed     Abstract available


    September 2020
  3. VALKEMA MJ, van der Wilk BJ, Eyck BM, Wijnhoven BPL, et al
    Surveillance of clinically complete responders using serial (18)F-FDG PET/CT scans in patients with esophageal cancer after neoadjuvant chemoradiotherapy.
    J Nucl Med. 2020 Sep 4. pii: jnumed.120.247981. doi: 10.2967/jnumed.120.247981.
    PubMed     Abstract available


    August 2020
  4. NICOLAY NH, Ruhle A, Wiedenmann N, Niedermann G, et al
    Lymphocyte Infiltration Determines the Hypoxia-Dependent Response to Definitive Chemoradiation in Head-and-Neck Cancer - Results from a Prospective Imaging Trial.
    J Nucl Med. 2020 Aug 28. pii: jnumed.120.248633. doi: 10.2967/jnumed.120.248633.
    PubMed     Abstract available


    May 2020
  5. CHENG L, Sa R, Luo Q, Fu H, et al
    Unexplained Hyperthyroglobulinemia in Differentiated Thyroid Cancer Patients Indicates Radioiodine Adjuvant Therapy: A Prospective Multicenter Study.
    J Nucl Med. 2020 May 1. pii: jnumed.120.243642. doi: 10.2967/jnumed.120.243642.
    PubMed     Abstract available


    April 2020
  6. PICCARDO A, Trimboli P, Bottoni G, Giovanella L, et al
    Radioiodine Ablation of Remaining Thyroid Lobe in Patients with Differentiated Thyroid Cancer Treated by Lobectomy. A systematic review and meta-analysis.
    J Nucl Med. 2020 Apr 24. pii: jnumed.120.244384. doi: 10.2967/jnumed.120.244384.
    PubMed     Abstract available


    March 2020
  7. DONOHOE KJ, Aloff J, Avram AM, Bennet KG, et al
    Appropriate Use Criteria for Nuclear Medicine in the Evaluation and Treatment of Differentiated Thyroid Cancer.
    J Nucl Med. 2020;61:375-396.
    PubMed    


  8. WU D, Gomes Lima CJ, Bloom G, Burman KD, et al
    Nationwide Survey on Implementation of 2011 Nuclear Regulatory Commission Policy on Release of Patients After (131)I Therapy for Thyroid Cancer.
    J Nucl Med. 2020;61:397-404.
    PubMed     Abstract available


  9. WU J, Gensheimer MF, Zhang N, Guo M, et al
    Tumor Subregion Evolution-Based Imaging Features to Assess Early Response and Predict Prognosis in Oropharyngeal Cancer.
    J Nucl Med. 2020;61:327-336.
    PubMed     Abstract available


    January 2020
  10. VERMANDEL M, Debruyne P, Beron A, Devos L, et al
    Management of patients with renal failure undergoing dialysis during (131)I therapy for thyroid cancer.
    J Nucl Med. 2020 Jan 10. pii: jnumed.119.232017. doi: 10.2967/jnumed.119.232017.
    PubMed     Abstract available


    October 2019
  11. GREENSPAN BS, Siegel JA, Hassan A, Silberstein EB, et al
    There is No Association of Radioactive Iodine Treatment with Cancer Mortality in Patients with Hyperthyroidism.
    J Nucl Med. 2019 Oct 4. pii: jnumed.119.235929. doi: 10.2967/jnumed.119.235929.
    PubMed    


  12. CHEN W, Dilsizian V
    Radioactive Iodine Treatment and Cancer Mortality in Hyperthyroid Patients: Concerns with Study Design and Bias.
    J Nucl Med. 2019 Oct 4. pii: jnumed.119.234849. doi: 10.2967/jnumed.119.234849.
    PubMed    


    September 2019
  13. ROTTENBURGER C, Nicolas GP, McDougall L, Kaul F, et al
    Cholecystokinin-2 Receptor Agonist (177)Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma - Results of the Lumed Phase 0a Study.
    J Nucl Med. 2019 Sep 13. pii: jnumed.119.233031. doi: 10.2967/jnumed.119.233031.
    PubMed     Abstract available


    August 2019
  14. LIU J, Liu R, Shen X, Zhu G, et al
    The Genetic Duet of BRAF V600E and TERT Promoter Mutations Robustly Predicts the Loss of Radioiodine Avidity in Recurrent Papillary Thyroid Cancer.
    J Nucl Med. 2019 Aug 2. pii: jnumed.119.227652. doi: 10.2967/jnumed.119.227652.
    PubMed     Abstract available


    June 2019
  15. LIU JTC, Sanai N
    Trends and Challenges for the Clinical Adoption of Fluorescence-Guided Surgery.
    J Nucl Med. 2019;60:756-757.
    PubMed    


  16. VAN NOSTRAND D
    Sites Performing Dosimetry for Selection of Activity for (131)I Therapy for Differentiated Thyroid Cancer.
    J Nucl Med. 2019;60:20N-22N.
    PubMed    


  17. MEERSHOEK P, van den Berg NS, Brouwer OR, Teertstra HJ, et al
    Three-Dimensional Tumor Margin Demarcation Using the Hybrid Tracer Indocyanine Green-(99m)Tc-Nanocolloid: A Proof-of-Concept Study in Tongue Cancer Patients Scheduled for Sentinel Node Biopsy.
    J Nucl Med. 2019;60:764-769.
    PubMed     Abstract available


    May 2019
  18. THORWARTH D, Welz S, Monnich D, Pfannenberg C, et al
    Prospective evaluation of a tumor control probability model based on dynamic (18)F-FMISO PET for head-and-neck cancer radiotherapy.
    J Nucl Med. 2019 May 10. pii: jnumed.119.227744. doi: 10.2967/jnumed.119.227744.
    PubMed     Abstract available


    March 2019
  19. VALKEMA MJ, Noordman BJ, Wijnhoven BPL, Spaander MCW, et al
    Accuracy of (18)F-FDG PET/CT in predicting residual disease after neoadjuvant chemoradiotherapy for esophageal cancer.
    J Nucl Med. 2019 Mar 15. pii: jnumed.118.224196. doi: 10.2967/jnumed.118.224196.
    PubMed     Abstract available


  20. ROLL W, Markwardt NA, Masthoff M, Helfen A, et al
    Multispectral optoacoustic tomography of benign and malignant thyroid disorders - a pilot study.
    J Nucl Med. 2019 Mar 8. pii: jnumed.118.222174. doi: 10.2967/jnumed.118.222174.
    PubMed     Abstract available


    February 2019
  21. WATABE T, Kaneda-Nakashima K, Liu Y, Shirakami Y, et al
    Enhancement of astatine-211 uptake via the sodium iodide symporter by the addition of ascorbic acid in targeted alpha therapy of thyroid cancer.
    J Nucl Med. 2019 Feb 22. pii: jnumed.118.222638. doi: 10.2967/jnumed.118.222638.
    PubMed     Abstract available


  22. VAN KEULEN S, Nishio N, Fakurnejad S, Birkeland A, et al
    The Clinical Application of Fluorescence-Guided Surgery in Head and Neck Cancer.
    J Nucl Med. 2019 Feb 7. pii: jnumed.118.222810. doi: 10.2967/jnumed.118.222810.
    PubMed     Abstract available


    November 2018
  23. SELVAKUMAR T, Nies M, Klein Hesselink MS, Brouwers AH, et al
    Long-term effects of radioiodine treatment on salivary gland function in adult survivors of pediatric differentiated thyroid carcinoma.
    J Nucl Med. 2018 Nov 30. pii: jnumed.118.212449. doi: 10.2967/jnumed.118.212449.
    PubMed     Abstract available


  24. ELMOKH O, Taelmann V, Radojewski P, Roelli MA, et al
    MEK inhibition induces therapeutic iodine uptake in a murine model of anaplastic thyroid cancer.
    J Nucl Med. 2018 Nov 21. pii: jnumed.118.216721. doi: 10.2967/jnumed.118.216721.
    PubMed     Abstract available


    October 2018
  25. DE ROSE F, Braeuer M, Braesch-Andersen S, Otto AM, et al
    Galectin-3 targeting in thyroid orthotopic tumors opens new ways to characterize thyroid cancer.
    J Nucl Med. 2018 Oct 25. pii: jnumed.118.219105. doi: 10.2967/jnumed.118.219105.
    PubMed     Abstract available


  26. BIKAS A, Wu D, Bethancourt E, Orquiza M, et al
    Detection at public facilities of (131)I in patients treated for differentiated thyroid cancer: the frequency, sites, management by security agents, and recommended physician documentation for patients.
    J Nucl Med. 2018 Oct 25. pii: jnumed.118.213256. doi: 10.2967/jnumed.118.213256.
    PubMed     Abstract available


  27. ROHDE M, Nielsen AL, Pareek M, Johansen J, et al
    PET/CT versus standard imaging for prediction of survival in patients with recurrent head and neck squamous cell carcinoma.
    J Nucl Med. 2018 Oct 12. pii: jnumed.118.217976. doi: 10.2967/jnumed.118.217976.
    PubMed     Abstract available


  28. BACHER R, Hohberg M, Dietlein M, Wild M, et al
    Thyroid uptake and effective half-life of radioiodine in thyroid cancer patients at radioiodine therapy and follow-up whole-body scintigraphy either in hypothyroidism or under rhTSH.
    J Nucl Med. 2018 Oct 12. pii: jnumed.118.217638. doi: 10.2967/jnumed.118.217638.
    PubMed     Abstract available


  29. LEE H, Lazor JW, Assadsangabi R, Shah J, et al
    An imager's guide to perineural tumor spread in head and neck cancers: radiological footprints on (18)F-FDG PET with CT and MRI correlates.
    J Nucl Med. 2018 Oct 5. pii: jnumed.118.214312. doi: 10.2967/jnumed.118.214312.
    PubMed     Abstract available


    September 2018
  30. BURLEY TA, Pieve CD, Martins CD, Ciobota DM, et al
    Affibody-based PET imaging to guide EGFR-targeted cancer therapy in head and neck squamous cell cancer models.
    J Nucl Med. 2018 Sep 13. pii: jnumed.118.216069. doi: 10.2967/jnumed.118.216069.
    PubMed     Abstract available


  31. KREISSL M, Janssen M, Nagarajah J
    Current treatment strategies in metastasized differentiated thyroid cancer.
    J Nucl Med. 2018 Sep 6. pii: jnumed.117.190819. doi: 10.2967/jnumed.117.190819.
    PubMed     Abstract available


    August 2018
  32. SCHENKE S, Seifert P, Zimny M, Winkens T, et al
    Risk stratification of thyroid nodules using Thyroid Imaging Reporting And Data System (TIRADS): The omission of thyroid scintigraphy increases the rate of falsely suspected lesions.
    J Nucl Med. 2018 Aug 10. pii: jnumed.118.211912. doi: 10.2967/jnumed.118.211912.
    PubMed     Abstract available


    June 2018
  33. PRYMA DA
    Controversies in the Use of Radioiodine in Thyroid Cancer: We Need More and Better Data.
    J Nucl Med. 2018 Jun 22. pii: jnumed.118.214197. doi: 10.2967/jnumed.118.214197.
    PubMed    


    May 2018
  34. SCHMIDT M, Gorges R, Drzezga A, Dietlein M, et al
    Radioiodine therapy in differentiated thyroid cancer - a matter of controversy - PRO Radioiodine.
    J Nucl Med. 2018 May 10. pii: jnumed.117.191338. doi: 10.2967/jnumed.117.191338.
    PubMed     Abstract available


    April 2018
  35. TULCHINSKY M, Binse I, Campenni A, Dizdarevic S, et al
    Radioactive Iodine Therapy for Differentiated Thyroid Cancer: Lessons from Confronting Controversial Literature on Risks for Secondary Malignancy.
    J Nucl Med. 2018 Apr 13. pii: jnumed.118.211359. doi: 10.2967/jnumed.118.211359.
    PubMed    


  36. TUTTLE RM
    Controversial Issues in Thyroid Cancer Management.
    J Nucl Med. 2018 Apr 13. pii: jnumed.117.192559. doi: 10.2967/jnumed.117.192559.
    PubMed     Abstract available


    March 2018
  37. SPANU A, Nuvoli S, Gelo I, Mele L, et al
    The role of diagnostic (131)I-SPECT/TC in patients with papillary thyroid microcarcinoma in long-term follow-up.
    J Nucl Med. 2018 Mar 1. pii: jnumed.117.204636. doi: 10.2967/jnumed.117.204636.
    PubMed     Abstract available


    December 2017
  38. TESSELAAR MH, Crezee T, Schuurmans I, Gerrits D, et al
    Digitalis-like compounds restore hNIS expression and iodide uptake capacity in anaplastic thyroid cancer.
    J Nucl Med. 2017 Dec 14. pii: jnumed.117.200675. doi: 10.2967/jnumed.117.200675.
    PubMed     Abstract available


    October 2017
  39. WERNER RA, Schmid JS, Higuchi T, Javadi MS, et al
    Predictive value of FDG-PET in patients with advanced medullary thyroid carcinoma treated with vandetanib.
    J Nucl Med. 2017 Oct 12. pii: jnumed.117.199778. doi: 10.2967/jnumed.117.199778.
    PubMed     Abstract available


  40. PATTISON DA, Bozin M, Gorelik A, Hofman MS, et al
    18F-fluorodeoxyglycose-avid thyroid incidentalomas: the importance of contextual interpretation.
    J Nucl Med. 2017 Oct 12. pii: jnumed.117.198085. doi: 10.2967/jnumed.117.198085.
    PubMed     Abstract available


    September 2017
  41. ROHDE M, Nielsen AL, Pareek M, Johansen J, et al
    A PET/CT-based strategy is a stronger predictor of survival than a standard imaging strategy in patients with head and neck squamous cell carcinoma.
    J Nucl Med. 2017 Sep 1. pii: jnumed.117.197350. doi: 10.2967/jnumed.117.197350.
    PubMed     Abstract available


    June 2017
  42. O'DONOGHUE JA, Lewis JS, Pandit-Taskar N, Fleming SE, et al
    Pharmacokinetics, biodistribution, and radiation dosimetry for 89Zr-trastuzumab in patients with esophagogastric cancer.
    J Nucl Med. 2017 Jun 21. pii: jnumed.117.194555. doi: 10.2967/jnumed.117.194555.
    PubMed     Abstract available


  43. NA KJ, Choi H
    Tumor metabolic features identified by FDG PET correlates with gene networks of immune cell microenvironment in head and neck cancer.
    J Nucl Med. 2017 Jun 6. pii: jnumed.117.194217. doi: 10.2967/jnumed.117.194217.
    PubMed     Abstract available


  44. ROHDE M, Nielsen AL, Johansen J, Sorensen JA, et al
    Head-to-head comparison of chest x-ray/head and neck MRI, chest CT/head and neck MRI, and 18F-FDG-PET/CT for detection of distant metastases and synchronous cancer in oral, pharyngeal, and laryngeal Cancer.
    J Nucl Med. 2017 Jun 1. pii: jnumed.117.189704. doi: 10.2967/jnumed.117.189704.
    PubMed     Abstract available


    May 2017
  45. XI M, Liao Z, Hofstetter WL, Komaki R, et al
    FDG-PET Response After Induction Chemotherapy Can Predict Who Will Benefit From Subsequent Esophagectomy After Chemoradiotherapy for Esophageal Adenocarcinoma.
    J Nucl Med. 2017 May 18. pii: jnumed.117.192591. doi: 10.2967/jnumed.117.192591.
    PubMed     Abstract available


    April 2017
  46. DEANDREIS D, Schlumberger M, Tuttle RM
    Reply: Fixed 100 mCi I-131 Activity for Metastatic Thyroid Cancer Therapy Ignores Science and History.
    J Nucl Med. 2017 Apr 27. pii: jnumed.117.193185. doi: 10.2967/jnumed.117.193185.
    PubMed    


  47. NICHOLS KJ, Robeson W, Yoshida-Hay M, Zanzonico PB, et al
    Alternative Means of Estimating 131I Maximum Permissible Activity to Treat Thyroid Cancer.
    J Nucl Med. 2017 Apr 13. pii: jnumed.117.192278. doi: 10.2967/jnumed.117.192278.
    PubMed     Abstract available


  48. O' DOHERTY J, Jauregui-Osoro M, Brothwood T, Szyszko T, et al
    18F-tetrafluoroborate (18F-TFB), a PET probe for imaging sodium-iodide symporter expression: Whole-body biodistribution, safety and radiation dosimetry in thyroid cancer patients.
    J Nucl Med. 2017 Apr 6. pii: jnumed.117.192252. doi: 10.2967/jnumed.117.192252.
    PubMed     Abstract available


  49. JENTZEN W, Nahum AE, Bockisch A, Binse I, et al
    Fixed 100 mCi I-131 Activity for Metastatic Thyroid Cancer Therapy Ignores Science and History.
    J Nucl Med. 2017 Apr 6. pii: jnumed.117.192872. doi: 10.2967/jnumed.117.192872.
    PubMed    


    February 2017
  50. VAN NOSTRAND D
    Prescribed activities of I-131 therapies in differentiated thyroid cancer: Invited Commentary.
    J Nucl Med. 2017 Feb 16. pii: jnumed.116.188862. doi: 10.2967/jnumed.116.188862.
    PubMed    


  51. FLUX GD, Verburg FA, Chiesa C, Bardies M, et al
    Comparison of empiric versus whole body/blood clearance dosimetry-based approach to radioactive iodine treatment in patients with metastases from differentiated thyroid cancer.
    J Nucl Med. 2017 Feb 9. pii: jnumed.116.186643. doi: 10.2967/jnumed.116.186643.
    PubMed    


    January 2017
  52. PLYKU D, Hobbs RF, Huang K, Atkins F, et al
    Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal in 124I-PET/CT based dosimetry for 131I therapy of metastatic differentiated thyroid cancer.
    J Nucl Med. 2017 Jan 19. pii: jnumed.116.179366. doi: 10.2967/jnumed.116.179366.
    PubMed     Abstract available


    October 2016
  53. DEANDREIS D, Rubino C, Tala H, Leboulleux S, et al
    Comparison Of Empiric Versus Whole Body/Blood Clearance Dosimetry-Based Approach To Radioactive Iodine Treatment In Patients With Metastases From Differentiated Thyroid Cancer.
    J Nucl Med. 2016 Oct 13. pii: jnumed.116.179606.
    PubMed     Abstract available


    August 2016
  54. YANG X, Li J, Li X, Liang Z, et al
    TERT promoter mutation predicts radioiodine refractory in distant metastatic differentiated thyroid cancer.
    J Nucl Med. 2016 Aug 4. pii: jnumed.116.180240.
    PubMed     Abstract available


    May 2016
  55. JENTZEN W, Verschure F, van Zon A, van de Kolk R, et al
    Response Assessment of Bone Metastases from Differentiated Thyroid Cancer Patients in the Initial Radioiodine Treatment Using Iodine-124 PET Imaging.
    J Nucl Med. 2016 May 19. pii: jnumed.115.170571.
    PubMed     Abstract available


  56. LIN CY, Lin CL, Kao CH
    Reply: Risk of Breast Cancer in Patients with Thyroid Cancer Receiving I-131 Treatment: Is There an Immortal Time Bias?
    J Nucl Med. 2016 May 19. pii: jnumed.116.178152.
    PubMed    


  57. RUHLMANN M, Jentzen W, Ruhlmann V, Pettinato C, et al
    High Level of Agreement between Pretherapeutic 124I PET and Intratherapeutic 131I Images in Detecting Iodine-positive Thyroid Cancer Metastases.
    J Nucl Med. 2016 May 5. pii: jnumed.115.169649.
    PubMed     Abstract available


    March 2016
  58. PATTISON DA, Solomon B, Hicks RJ
    A New Theranostic Paradigm for Advanced Thyroid Cancer.
    J Nucl Med. 2016 Mar 31. pii: jnumed.116.173534.
    PubMed    


    February 2016
  59. WIERTS R, Brans B, Havekes B, Kemerink G, et al
    Dose-response Relationship in Differentiated Thyroid Cancer Patients Undergoing Radioiodine Treatment Assessed by Means of 124I PET/CT.
    J Nucl Med. 2016 Feb 25. pii: jnumed.115.168799.
    PubMed     Abstract available


  60. LIN CM, Yeh PT, Doyle P, Tsan YT, et al
    Association between 131I treatment for thyroid cancer and risk of receiving cataract surgery-a cohort study from Taiwan.
    J Nucl Med. 2016 Feb 2. pii: jnumed.115.167197.
    PubMed     Abstract available


    December 2015
  61. LIN CY, Lin CL, Huang WS, Kao CH, et al
    Risk of Breast Cancer in Patients With Thyroid Cancer Receiving or Not Receiving I-131 Treatment: A Nationwide Population-based Cohort Study.
    J Nucl Med. 2015 Dec 30. pii: jnumed.115.164830.
    PubMed     Abstract available


    November 2015
  62. KIST JW, de Keizer B, van der Vlies M, Brouwers AH, et al
    124I PET/CT to predict the outcome of blind 131I treatment in patients with biochemical recurrence of differentiated thyroid cancer; results of a multicenter diagnostic cohort study (THYROPET).
    J Nucl Med. 2015 Nov 25. pii: jnumed.115.168138.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Head and Neck Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: